Ginkgo Bioworks (NYSE:DNA – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its competitors? We will compare Ginkgo Bioworks to similar companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, earnings and analyst recommendations.
Valuation and Earnings
This table compares Ginkgo Bioworks and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ginkgo Bioworks | $170.15 million | -$312.76 million | -2.91 |
| Ginkgo Bioworks Competitors | $2.26 billion | $55.88 billion | -7.91 |
Ginkgo Bioworks’ competitors have higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Ginkgo Bioworks has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks’ competitors have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Ginkgo Bioworks and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
| Ginkgo Bioworks Competitors | 954 | 3181 | 5515 | 178 | 2.50 |
Ginkgo Bioworks currently has a consensus price target of $7.00, suggesting a potential downside of 42.79%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.29%. Given Ginkgo Bioworks’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Ginkgo Bioworks has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Ginkgo Bioworks and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
| Ginkgo Bioworks Competitors | -538.51% | -166.21% | -13.47% |
Summary
Ginkgo Bioworks competitors beat Ginkgo Bioworks on 8 of the 13 factors compared.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
-ltd-logo-1200x675.png){kind=logo}
